Does Whole Blood Adsorber During CPB Reduce Vasoactive Drugs Postoperatively in Endocarditis Patients Undergoing Valve Surgery?

Does Whole Blood Adsorber During CPB Reduce the Amount of Vasoactive Drugs Postoperatively in Endocarditis Patients Undergoing Valve Surgery? -a Randomized Controlled Study

Status

Completed

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT03945708

Enrollment

Registered

2019-05-10

Start date

2019-05-15

Completion date

2020-12-31

Last updated

2021-09-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Infective Endocarditis

Brief summary

The study aims to investigate the effect of addition of an adsorber during cardio pulmonary bypassin patients with infective endocarditis undergoing valve surgery, and if it will decrease the use of vasoactive drugs postoperatively.

Interventions

DEVICECytoSorb

Addition of a hemofilter to the cardiopulmonary bypass circuit

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

SUPPORTIVE_CARE

Masking

SINGLE (Outcomes Assessor)

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

1. Infected endocarditis patients undergoing heart valve surgery. 2. Age over 18 years.

Exclusion criteria

1 Declines participation

Design outcomes

Primary

Measure	Time frame	Description
Use of vasoactive substances	48 hours	Use of norepinephrine in ICU

Secondary

Measure	Time frame	Description
Milrinone use	48 hours	Amount of milrinone used 24 and 48 hours postoperatively
Chest tube bleeding	48 hours	Chest tube output in ml
Blood transfusions	48 hours	Transfusion of red blood cells, plasma and platelets

Countries

Sweden

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026